Title: Recent Developments in Patented DC-Based Immunotherapy for Various Malignancies
Volume: 1
Issue: 1
Author(s): Yui Harada and Yoshikazu Yonemitsu
Affiliation:
Keywords:
Antigen, dendritic cell (DC), expansion, immunotherapy, malignancies, maturation, cancer vaccine, novel technologies, cardiovascular disease, chemotherapy, radiotherapy, interferon (IFN), cytokine-based immunotherapies, cytotoxic T lymphocyte (CTL), Monocyte-Dendritic cell Progenitor (MDP), T-cell receptor (TCR), prostaglandin E2 (PGE2), cancer immunosurveillance, lymphatic vessels, lymphoid organs, hall tumor lysate, apoptosis-resisting ligands, delayed type hypersensitivity (DTH), Eli-spot assays, alloreactivity, immunostimulatory milieu, lymphocytic leukemia, melanoma vaccine, melanoma antigens, intracranial glial tumors, cord blood (CB), immunosuppressive cytokines, Sendai virus (SeV), hemagglutinins, paramyxoviruses, autologous cellular therapy, Monocyte Expansion, proto-onocogene, carboxy-terminal region, bone marrow progenitors, Kaplan-Meier method, dose-efficacy response, stem cell factor, cytokine cocktail, mixed lymphocyte reaction (MLR), pluripotency, myeloid precursor cells, teratoma, Good Manufacturing Practice (GMP)
Abstract: Dendritic cells (DCs) play a crucial role in maintaining the immune system. DC-based immunotherapy is known as the “cancer vaccine” for advanced cancers and to prevent recurrence. Though DC-based cancer immunotherapy has been suggested as a potential treatment for various kinds of malignancies, its clinical efficacies in many human trials are still insufficient. To identify the causes of these low efficacies, many investigators have focused on the numbers of administered DCs, how they are activated, which type is best, and so on. This review focuses primarily on patents analysis of recently developed DC-based cancer immunotherapies. We also analyze the critical factors of DC-based cancer immunotherapy to best optimize the development of these novel technologies.
